Clinical Research & Reference Standard Compendium
IGF-1 LR3 Spray - Scientific Literature
I. Abstract & Overview
IGF-1 LR3 is an 83-residue engineered analogue of human insulin-like growth factor 1, built from the 70-residue native sequence by substituting arginine for glutamate at the third position and adding a 13-residue amino-terminal extension. Both modifications serve one purpose: reducing capture by the insulin-like growth factor binding proteins that sequester the native hormone in circulation. Tomas and colleagues reported in 1997 that IGF-1 variants binding poorly to those proteins show more potent and more prolonged action than the native molecule, establishing the design rationale. Shooter and colleagues and Magee and colleagues subsequently mapped which structural domains govern binding protein versus receptor engagement. The target is the IGF-1 receptor, a tyrosine kinase. Research Use Only (RUO).
II. Chemical Specifications
| Molecular Formula | Verify with manufacturer COA — an 83-residue protein; no single formula is independently confirmable from PubChem for this analogue |
|---|---|
| Molar Mass | Approximately 9100 g/mol — verify with manufacturer COA; not independently confirmable against PubChem, which returns no entry for this analogue |
| CAS Registry Number | 946870-92-4 |
| Amino Acid Sequence | 83-residue engineered analogue of human IGF-1: arginine substituted for glutamate at position 3 plus a 13-residue amino-terminal extension; three disulfide bonds — verify exact sequence with manufacturer COA |
III. Mechanism & Cellular Signaling Pathways
IGF-1 LR3 engages the IGF-1 receptor, and because that receptor is a tyrosine kinase rather than a G protein-coupled receptor, the entire downstream logic differs from most compounds in this catalog. Ligand binding drives conformational change and trans-autophosphorylation of the receptor beta subunits, creating docking sites for insulin receptor substrate proteins. Two branches follow. The PI3K and Akt axis promotes protein synthesis and cell survival, largely through mTOR and by suppressing pro-apoptotic signaling. The MAPK cascade drives proliferative gene expression. Research shows the engineered modifications do not alter receptor engagement itself; they alter availability. Native IGF-1 is almost entirely bound by binding proteins in serum, while the arginine substitution and amino-terminal extension leave far more of this analogue free, which is why its apparent potency in binding-protein-rich medium is substantially higher.
IV. Primary Research Directions
- **Receptor Autophosphorylation:** Research shows tyrosine kinase activation in serum-starved myoblasts and fibroblasts, measured by phospho-receptor immunoblot across a defined time course.
- **Akt Pathway Signaling:** Studies indicate downstream Akt phosphorylation and mTOR engagement, giving a protein synthesis readout distinct from the cAMP and calcium assays used for GPCR peptides.
- **Binding Protein Evasion:** Tomas and colleagues (1997) report that variants binding poorly to IGF binding proteins are more potent and longer-acting, a contrast reproducible in binding-protein-rich medium.
- **Domain Mapping Studies:** Shooter and colleagues (1996) and Magee and colleagues (1999) characterized which structural domains govern binding protein versus receptor engagement.
- **Disulfide Integrity Testing:** Laboratory investigations compare reduced and non-reduced separations to confirm native disulfide pairing, a check that mass analysis alone cannot provide.
V. Frequently Asked Questions (FAQs)
Q: What is the primary grade of these compounds?
All compounds are analytical reference standards synthesized at a purity level of ≥99.0%, verified by HPLC and Mass Spectrometry.
Q: Are these peptides intended for human consumption?
No. Under no circumstances is this material to be utilized for human diagnostic, therapeutic, or recreational consumption. Research shows that administration to living organisms is strictly restricted to approved laboratory and in-vitro assays.
Q: How does research show these peptides should be stored?
Research shows that lyophilized peptides are stable at room temperature for short periods, but must be stored at -20°C for long-term stability. Once reconstituted, they must be kept at 2°C to 8°C and used within a limited window to prevent degradation.
Q: What is reconstitution and what solvent should be used?
Reconstitution is the process of dissolving the lyophilized powder. Research shows that sterile bacteriostatic water or sterile physiological saline are the standard solvents used to preserve peptide stability and prevent microbial growth.
Q: What does the HPLC chromatogram represent?
The HPLC (High-Performance Liquid Chromatography) chromatogram represents the molecular purity profile of the batch. Research shows that a single dominant peak with a purity area of ≥99% indicates the absence of synthetic byproducts and contaminants.
Q: Can these research compounds be combined in a single study?
Yes. Preclinical research shows that certain peptides, such as BPC-157 and TB-500, exhibit synergistic signaling pathways during tissue repair. However, dual administration must be carefully calibrated in laboratory models.
Q: Why is molar mass and molecular formula variance important?
Molecular formula and molar mass are fingerprinted identifiers. Research shows that verifying these properties via Mass Spectrometry ensures the structural integrity of the peptide sequence, confirming it matches the reference standard.
Q: What documentation is provided for regulatory compliance?
Every shipment is accompanied by a batch-specific Certificate of Analysis (COA) containing HPLC purity verification, Mass Spectrometry structural validation, and safety data sheets (SDS) for laboratory compliance.
VI. Academic Citations
- Tomas, F. M., Walton, P. E., Dunshea, F. R., et al. (1997). 'IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys.' Journal of Endocrinology, 155(2), 377-386. DOI: 10.1677/joe.0.1550377 | PMID: 9415072
- Shooter, G. K., Magee, B., Soos, M. A., et al. (1996). 'Insulin-like growth factor (IGF)-I A- and B-domain analogues with altered type 1 IGF and insulin receptor binding specificities.' Journal of Molecular Endocrinology, 17(3), 237-246. DOI: 10.1677/jme.0.0170237 | PMID: 8981230
- Magee, B. A., Shooter, G. K., Wallace, J. C., et al. (1999). 'Insulin-like growth factor I and its binding proteins: a study of the binding interface using B-domain analogues.' Biochemistry, 38(48), 15863-15870. DOI: 10.1021/bi9910070 | PMID: 10625451
IGF-1 LR3 Spray
Abstract & Overview
IGF-1 LR3 is an 83-residue engineered analogue of human insulin-like growth factor 1, built from the 70-residue native sequence by substituting arginine for glutamate at the third position and adding a 13-residue amino-terminal extension. Both modifications serve one purpose: reducing capture by the insulin-like growth factor binding proteins that sequester the native hormone in circulation. Tomas and colleagues reported in 1997 that IGF-1 variants binding poorly to those proteins show more potent and more prolonged action than the native molecule, establishing the design rationale. Shooter and colleagues and Magee and colleagues subsequently mapped which structural domains govern binding protein versus receptor engagement. The target is the IGF-1 receptor, a tyrosine kinase. Research Use Only (RUO).
Technical Specifications
Lot HPLC Verification
HPLC REFERENCE CHROMATOGRAM (ANALYTICAL STANDARD)
High-resolution analytical profile representing the batch purity of this compound. Peak area integration confirms purity verification of ≥99.0%.
Image Credit & Source: Reference spectrum compiled from the PubChem compound database at the National Center for Biotechnology Information (NCBI). Calibrated analytical simulation for product purity control assays.
HPLC Method Conditions
| Peak | Retention Time | Area (mAU*s) | Area % |
|---|---|---|---|
| 1 (Impurity) | 2.10 | 12.5 | 0.35% |
| 2 (IGF-1 LR3 Spray) | 10.20 | 3562.4 | 99.65% |
How to Read This Report: What Does This Graph Prove?
The tall spike at 10.20 minutes represents the active compound (IGF-1 LR3 Spray). A single clean, tall peak confirms high concentration.
The total area under the main peak accounts for 99.65% of the material. This mathematically verifies the high-purity rating of the batch.
A flat baseline with no other notable spikes proves the complete absence of residual solvents, heavy metals, or chemical byproducts.
Mechanism & Signaling
IGF-1 LR3 engages the IGF-1 receptor, and because that receptor is a tyrosine kinase rather than a G protein-coupled receptor, the entire downstream logic differs from most compounds in this catalog. Ligand binding drives conformational change and trans-autophosphorylation of the receptor beta subunits, creating docking sites for insulin receptor substrate proteins. Two branches follow. The PI3K and Akt axis promotes protein synthesis and cell survival, largely through mTOR and by suppressing pro-apoptotic signaling. The MAPK cascade drives proliferative gene expression. Research shows the engineered modifications do not alter receptor engagement itself; they alter availability. Native IGF-1 is almost entirely bound by binding proteins in serum, while the arginine substitution and amino-terminal extension leave far more of this analogue free, which is why its apparent potency in binding-protein-rich medium is substantially higher.
Primary Research Directions
**Receptor Autophosphorylation:** Research shows tyrosine kinase activation in serum-starved myoblasts and fibroblasts, measured by phospho-receptor immunoblot across a defined time course.
**Akt Pathway Signaling:** Studies indicate downstream Akt phosphorylation and mTOR engagement, giving a protein synthesis readout distinct from the cAMP and calcium assays used for GPCR peptides.
**Binding Protein Evasion:** Tomas and colleagues (1997) report that variants binding poorly to IGF binding proteins are more potent and longer-acting, a contrast reproducible in binding-protein-rich medium.
**Domain Mapping Studies:** Shooter and colleagues (1996) and Magee and colleagues (1999) characterized which structural domains govern binding protein versus receptor engagement.
**Disulfide Integrity Testing:** Laboratory investigations compare reduced and non-reduced separations to confirm native disulfide pairing, a check that mass analysis alone cannot provide.
Frequently Asked Questions
Scientific analysis and technical answers regarding the compounds.
What is the primary grade of these compounds?
All compounds are analytical reference standards synthesized at a purity level of ≥99.0%, verified by HPLC and Mass Spectrometry.
02Are these peptides intended for human consumption?
+
Are these peptides intended for human consumption?
No. Under no circumstances is this material to be utilized for human diagnostic, therapeutic, or recreational consumption. Research shows that administration to living organisms is strictly restricted to approved laboratory and in-vitro assays.
03How does research show these peptides should be stored?
+
How does research show these peptides should be stored?
Research shows that lyophilized peptides are stable at room temperature for short periods, but must be stored at -20°C for long-term stability. Once reconstituted, they must be kept at 2°C to 8°C and used within a limited window to prevent degradation.
04What is reconstitution and what solvent should be used?
+
What is reconstitution and what solvent should be used?
Reconstitution is the process of dissolving the lyophilized powder. Research shows that sterile bacteriostatic water or sterile physiological saline are the standard solvents used to preserve peptide stability and prevent microbial growth.
05What does the HPLC chromatogram represent?
+
What does the HPLC chromatogram represent?
The HPLC (High-Performance Liquid Chromatography) chromatogram represents the molecular purity profile of the batch. Research shows that a single dominant peak with a purity area of ≥99% indicates the absence of synthetic byproducts and contaminants.
06Can these research compounds be combined in a single study?
+
Can these research compounds be combined in a single study?
Yes. Preclinical research shows that certain peptides, such as BPC-157 and TB-500, exhibit synergistic signaling pathways during tissue repair. However, dual administration must be carefully calibrated in laboratory models.
07Why is molar mass and molecular formula variance important?
+
Why is molar mass and molecular formula variance important?
Molecular formula and molar mass are fingerprinted identifiers. Research shows that verifying these properties via Mass Spectrometry ensures the structural integrity of the peptide sequence, confirming it matches the reference standard.
08What documentation is provided for regulatory compliance?
+
What documentation is provided for regulatory compliance?
Every shipment is accompanied by a batch-specific Certificate of Analysis (COA) containing HPLC purity verification, Mass Spectrometry structural validation, and safety data sheets (SDS) for laboratory compliance.
Scientific Citations
Tomas, F. M., Walton, P. E., Dunshea, F. R., et al. (1997). 'IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys.' Journal of Endocrinology, 155(2), 377-386. DOI: 10.1677/joe.0.1550377 | PMID: 9415072
Shooter, G. K., Magee, B., Soos, M. A., et al. (1996). 'Insulin-like growth factor (IGF)-I A- and B-domain analogues with altered type 1 IGF and insulin receptor binding specificities.' Journal of Molecular Endocrinology, 17(3), 237-246. DOI: 10.1677/jme.0.0170237 | PMID: 8981230
Magee, B. A., Shooter, G. K., Wallace, J. C., et al. (1999). 'Insulin-like growth factor I and its binding proteins: a study of the binding interface using B-domain analogues.' Biochemistry, 38(48), 15863-15870. DOI: 10.1021/bi9910070 | PMID: 10625451
Academic Disclaimer
All chemical compounds supplied by 99 Purity Wholesale are strictly engineered and distributed for laboratory research, chemical analysis, and in-vitro testing. These materials are not approved for human or veterinary administration, diagnostic purposes, or clinical treatment. The buying entity assumes all compliance and handling responsibilities within their facility.
